AU2008326784B2 - Non-nucleoside reverse transcriptase inhibitors - Google Patents

Non-nucleoside reverse transcriptase inhibitors Download PDF

Info

Publication number
AU2008326784B2
AU2008326784B2 AU2008326784A AU2008326784A AU2008326784B2 AU 2008326784 B2 AU2008326784 B2 AU 2008326784B2 AU 2008326784 A AU2008326784 A AU 2008326784A AU 2008326784 A AU2008326784 A AU 2008326784A AU 2008326784 B2 AU2008326784 B2 AU 2008326784B2
Authority
AU
Australia
Prior art keywords
alkyl
independently
chloro
pyridin
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008326784A
Other languages
English (en)
Other versions
AU2008326784A1 (en
Inventor
Neville Anthony
Robert Gomez
Samson M. Jolly
John T. Sisko
Thomas J. Tucker
Robert Tynebor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2008326784A1 publication Critical patent/AU2008326784A1/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Alteration of Name(s) of Applicant(s) under S113 Assignors: MERCK SHARP & DOHME CORP.
Application granted granted Critical
Publication of AU2008326784B2 publication Critical patent/AU2008326784B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008326784A 2007-11-20 2008-11-14 Non-nucleoside reverse transcriptase inhibitors Ceased AU2008326784B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US376907P 2007-11-20 2007-11-20
US61/003,769 2007-11-20
PCT/US2008/012774 WO2009067166A2 (en) 2007-11-20 2008-11-14 Non-nucleoside reverse transcriptase inhibitors

Publications (2)

Publication Number Publication Date
AU2008326784A1 AU2008326784A1 (en) 2009-05-28
AU2008326784B2 true AU2008326784B2 (en) 2014-04-24

Family

ID=40336474

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008326784A Ceased AU2008326784B2 (en) 2007-11-20 2008-11-14 Non-nucleoside reverse transcriptase inhibitors

Country Status (12)

Country Link
US (1) US8404856B2 (enExample)
EP (1) EP2222661B1 (enExample)
JP (1) JP5539216B2 (enExample)
KR (1) KR20100088142A (enExample)
CN (1) CN101952274A (enExample)
AU (1) AU2008326784B2 (enExample)
BR (1) BRPI0820162A2 (enExample)
CA (1) CA2705834A1 (enExample)
IL (1) IL205386A0 (enExample)
MX (1) MX2010005483A (enExample)
RU (1) RU2010125220A (enExample)
WO (1) WO2009067166A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010026075A1 (en) * 2008-09-04 2010-03-11 F. Hoffmann-La Roche Ag Pyridine derivatives as inhibitors of hiv-i reverse transcriptase
US20120232062A1 (en) * 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
CN102971308B (zh) 2010-03-30 2015-02-04 默克加拿大有限公司 非核苷类逆转录酶抑制剂
US20130040914A1 (en) * 2010-04-08 2013-02-14 Samson M. Jolly Prodrugs of an hiv reverse transcriptase inhibitor
EP2900240B1 (en) * 2012-09-26 2020-01-08 Merck Sharp & Dohme Corp. Crystalline form of a reverse transcriptase inhibitor
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
MX355439B (es) * 2012-12-05 2018-04-18 Merck Sharp & Dohme Proceso para preparar inhibidores de la transcriptasa inversa.
CA2930585A1 (en) * 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
RU2693622C2 (ru) 2014-04-01 2019-07-03 Мерк Шарп И Доум Корп. Пролекарственные средства ингибиторов обратной транскриптазы вич
DK3180335T3 (da) 2014-08-11 2021-08-09 Angion Biomedica Corp Cytokrom-p450-inhibitorer og anvendelser deraf
EP3240778A4 (en) 2014-12-31 2018-07-11 Angion Biomedica Corp. Methods and agents for treating disease
KR102185996B1 (ko) * 2015-09-23 2020-12-02 머크 샤프 앤드 돔 코포레이션 4'-치환된 뉴클레오시드 리버스 트랜스크립타제 억제제 및 그의 제조법
RU2750151C2 (ru) 2015-11-20 2021-06-22 Форма Терапьютикс, Инк. Гипоксантины в качестве ингибиторов убиквитин-специфической протеазы 1
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
JP7254078B2 (ja) 2017-11-27 2023-04-07 ダート・ニューロサイエンス・エルエルシー Ｐｄｅ１阻害剤としての置換フラノピリミジン化合物
MA54549A (fr) 2018-12-18 2022-03-30 Merck Sharp & Dohme Dérivés de pyrimidone en tant qu'agents cytotoxiques sélectifs contre des cellules infectées par le vih
CN114026081B (zh) * 2019-05-22 2025-02-11 默沙东有限责任公司 作为针对hiv感染的细胞的选择性细胞毒性剂的吡啶酮衍生物
CN110066273A (zh) * 2019-06-05 2019-07-30 山东大学 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
CN112876409A (zh) * 2021-01-20 2021-06-01 都创(上海)医药科技股份有限公司 一种2-(5-溴-6-甲氧基吡啶-2-基)乙腈及其衍生物的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055676A1 (en) * 1998-04-27 1999-11-04 Centre National De La Recherche Scientifique 3-(amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of hiv related diseases
WO2007015809A2 (en) * 2005-07-22 2007-02-08 Merck & Co., Inc. Hiv reverse transcriptase inhibitors
WO2008098143A2 (en) * 2007-02-08 2008-08-14 Trius Therapeutics Antimicrobial compounds and methods of use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
WO1995004045A1 (en) * 1993-07-28 1995-02-09 Rhone-Poulenc Rorer Limited Compounds as pde iv and tnf inhibitors
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
US6800651B2 (en) * 2000-02-03 2004-10-05 Eli Lilly And Company Potentiators of glutamate receptors
DK1318997T3 (da) 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
WO2002024650A2 (en) * 2000-09-19 2002-03-28 Centre National De La Recherche Scientifique (Cnrs) Pyridinone and pyridinethione derivatives having hiv inhibiting properties
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
ES2334990T3 (es) * 2002-02-14 2010-03-18 Pharmacia Corporation Piridinonas sustituidas como moduladores de p38 map quinasa.
CL2004000192A1 (es) 2003-02-07 2005-03-18 Janssen Pharmaceutica Nv Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
EP1608629A1 (en) * 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
WO2004096147A2 (en) * 2003-04-28 2004-11-11 Idenix (Cayman) Limited Oxo-pyrimidine compounds
US7166738B2 (en) * 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
DK1742908T3 (da) 2004-04-23 2010-01-18 Hoffmann La Roche Ikke nukleosid revers transkriptase inhibitorer
TWI360539B (en) * 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
EP1831157A2 (en) * 2004-12-22 2007-09-12 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
BRPI0617720A2 (pt) * 2005-10-19 2011-08-02 Hoffmann La Roche compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém
ES2320042T3 (es) 2005-10-19 2009-05-18 F. Hoffmann-La Roche Ag Inhibidores de transcriptasa reversa con nucleosidos de n-fenil fenilacetamida.
EP2038272B8 (en) * 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055676A1 (en) * 1998-04-27 1999-11-04 Centre National De La Recherche Scientifique 3-(amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of hiv related diseases
WO2007015809A2 (en) * 2005-07-22 2007-02-08 Merck & Co., Inc. Hiv reverse transcriptase inhibitors
WO2008098143A2 (en) * 2007-02-08 2008-08-14 Trius Therapeutics Antimicrobial compounds and methods of use

Also Published As

Publication number Publication date
WO2009067166A2 (en) 2009-05-28
EP2222661B1 (en) 2016-04-20
CA2705834A1 (en) 2009-05-28
RU2010125220A (ru) 2011-12-27
IL205386A0 (en) 2010-12-30
JP5539216B2 (ja) 2014-07-02
KR20100088142A (ko) 2010-08-06
WO2009067166A3 (en) 2009-07-16
US20100256181A1 (en) 2010-10-07
AU2008326784A1 (en) 2009-05-28
CN101952274A (zh) 2011-01-19
JP2011503230A (ja) 2011-01-27
BRPI0820162A2 (pt) 2019-09-24
US8404856B2 (en) 2013-03-26
EP2222661A2 (en) 2010-09-01
MX2010005483A (es) 2010-06-11

Similar Documents

Publication Publication Date Title
AU2008326784B2 (en) Non-nucleoside reverse transcriptase inhibitors
JP6982343B2 (ja) 治療用阻害化合物
US7781454B2 (en) Non-nucleoside reverse transcriptase inhibitors
CN101268073B (zh) 杂环化合物、制备方法及其用途
CN104884454B (zh) 用作IL‑12、IL‑23和/或IFNα应答调节剂的酰胺取代的杂环化合物
CN103038229B (zh) 杂芳基化合物及其使用方法
CN106660960B (zh) 用作IL-12、IL-23和/或IFNα响应的调节剂的烷基-酰胺-取代的吡啶化合物
TW201823243A (zh) Tyk2抑制劑及其用途
WO2017066014A1 (en) Bruton's tyrosine kinase inhibitors
JP2011510004A (ja) タンパク質キナーゼ阻害剤及びその使用
AU2012250059A1 (en) Aldosterone synthase inhibitors
CN111278814B (zh) 作为毒蕈碱m1受体正向别构调节剂的多环酰胺
EP1928455A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
JP5264772B2 (ja) ピロロピリジン−２−カルボキサミドの誘導体、これらの調製およびこれらの治療用途
AU2003277562B2 (en) Pyrazolonaphthyridine derivative
KR20150039656A (ko) 술포닐인돌 유도체 및 이의 제조방법
JP6298071B2 (ja) ピリドン誘導体および結核の処置におけるその使用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired